Table 1 Clinicopathological features and operative course
From: Developments in esophageal surgery for adenocarcinoma: a comparison of two decades
|  | Decade I (9/1985–9/1995) (n = 48) | Decade II (10/1995–9/2005) (n = 127) | p-value |
|---|---|---|---|
age (years) | 62.1 (41–78.3) | 62.6 (28.9–79.9) | n.s. |
gender (males) | 43 (89.6%) | 110 (86.6%) | n.s. |
ASA-classification | Â | Â | Â |
-ASA I | 0 | 0 | Â |
-ASA II | 14 (30.4%) | 58 (47.9%) | 0.008* |
-ASA III | 27 (58.7%) | 61 (50.4%) | Â |
-ASA IV | 5 (10.9%) | 2 (1.7%) | Â |
tumor site | Â | Â | Â |
-middle third | 8 (16.7%) | 8 (6.3%) | n.s. |
-lower third | 40 (83.3%) | 118 (93.7%) | Â |
UICC-classification | Â | Â | Â |
-I | 6 (12.8%) | 18 (14.3%) | Â |
-IIA | 9 (19.1%) | 19 (15.1%) | 0.017* |
-IIB | 0 | 24 (19%) | Â |
-III | 18 (38.3%) | 30 (23.8%) | Â |
-IV | 14 (29.8%) | 35 (27.8%) | Â |
R-classification | Â | Â | Â |
-R0 | 40 (83.3%) | 115 (91.3%) | n.s. |
-R1 | 6 (12.5%) | 10 (7.9%) | Â |
-R2 | 2 (4.2%) | 1 (0.8%) | Â |
operative procedure | Â | Â | Â |
-transhiatal | 16 (33.3%) | 107 (84.3%) | <0.0001* |
-transthoracic | 32 (66.7%) | 20 (15.7%) | Â |
number of lymph nodes | Â | Â | Â |
-dissected | 19 (0–93) | 23 (3–79) | n.s. |
-involved | 2 (0–76) | 3 (0–33) | n.s. |
30-day mortality | 4 (8.3%) | 4 (3.1%) | n.s. |